Abstract：
BACKGROUND: Invasive fungal diseases (IFD) remain a major complication of allogeneic hematopoietic stem cell transplantation (alloHSCT) and are associated with high mortality rates in patients receiving alloHSCT. Antifungal prophylaxis is increasingly being used in the management of IFDs in patients receiving alloHSCT.
METHODS: A post-hoc analysis of the cross-sectional observational AFHEM study was carried out to describe the use of antifungal drugs in real-life clinical practice in alloHSCT recipients hospitalized in French hematological units.
RESULTS: A total of 147 alloHSCT recipients were enrolled; most were adults (n = 135; 92%) and had received alloHSCT < 6 months prior to enrollment (n = 123; 84%). Overall, 119 (81%) patients received a systemic antifungal therapy; of these, 95 (80%) patients received antifungal prophylaxis. Rates of patients receiving systemic antifungal treatment were similar irrespective of transplant time, neutropenic, and graft-versus-host disease status. Among patients on systemic antifungal treatment, 83 (70%) received an azole, 22 (18%) received an echinocandin, and 16 (13%) received a polyene.
CONCLUSIONS: This work provides evidence of the antifungal strategies used in alloHSCT recipients hospitalized in French hematological units. Unlike earlier studies, the AFHEM study showed that prophylaxis appears to be the leading antifungal strategy used in alloHSCT recipients in France.
METHODS: A post-hoc analysis of the cross-sectional observational AFHEM study was carried out to describe the use of antifungal drugs in real-life clinical practice in alloHSCT recipients hospitalized in French hematological units.
RESULTS: A total of 147 alloHSCT recipients were enrolled; most were adults (n = 135; 92%) and had received alloHSCT < 6 months prior to enrollment (n = 123; 84%). Overall, 119 (81%) patients received a systemic antifungal therapy; of these, 95 (80%) patients received antifungal prophylaxis. Rates of patients receiving systemic antifungal treatment were similar irrespective of transplant time, neutropenic, and graft-versus-host disease status. Among patients on systemic antifungal treatment, 83 (70%) received an azole, 22 (18%) received an echinocandin, and 16 (13%) received a polyene.
CONCLUSIONS: This work provides evidence of the antifungal strategies used in alloHSCT recipients hospitalized in French hematological units. Unlike earlier studies, the AFHEM study showed that prophylaxis appears to be the leading antifungal strategy used in alloHSCT recipients in France.
摘要：
背景：侵袭性真菌病（IFD）仍然是异基因造血干细胞移植（alloHSCT）的主要并发症，并且与接受alloHSCT的患者的高死亡率相关。抗真菌预防越来越多地用于接受alloHSCT的患者的IFD管理。
方法：对AFHEM横断面观察性研究进行了事后分析，以描述在法国血液学单位住院的alloHSCT受者的实际临床实践中抗真菌药物的使用。
结果：共有147名alloHSCT受者入组；大多数为成人（n=135；92%），且在入组前6个月内已接受alloHSCT（n=123；84%）。总的来说,119例(81%)患者接受了全身抗真菌治疗；其中，95（80％）患者接受了抗真菌预防。无论移植时间如何，接受全身抗真菌治疗的患者比率相似。中性粒细胞减少,和移植物抗宿主病状态。在接受全身抗真菌治疗的患者中，83（70％）接受唑，22人（18%）接受了棘白菌素，16（13％）获得了多烯。
结论：这项工作提供了在法国血液单位住院的alloHSCT受者中使用抗真菌策略的证据。与早期的研究不同，AFHEM研究表明,预防似乎是法国alloHSCT受者使用的主要抗真菌策略.
方法：对AFHEM横断面观察性研究进行了事后分析，以描述在法国血液学单位住院的alloHSCT受者的实际临床实践中抗真菌药物的使用。
结果：共有147名alloHSCT受者入组；大多数为成人（n=135；92%），且在入组前6个月内已接受alloHSCT（n=123；84%）。总的来说,119例(81%)患者接受了全身抗真菌治疗；其中，95（80％）患者接受了抗真菌预防。无论移植时间如何，接受全身抗真菌治疗的患者比率相似。中性粒细胞减少,和移植物抗宿主病状态。在接受全身抗真菌治疗的患者中，83（70％）接受唑，22人（18%）接受了棘白菌素，16（13％）获得了多烯。
结论：这项工作提供了在法国血液单位住院的alloHSCT受者中使用抗真菌策略的证据。与早期的研究不同，AFHEM研究表明,预防似乎是法国alloHSCT受者使用的主要抗真菌策略.
